Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Supreme Court rejects statistical significance as bright-line rule for materiality

Katten Muchin Rosenman LLP
-
USA
-
March 25 2011

The U.S. Supreme Court found that allegations of "statistical significance" were not a requirement for pleading materiality in a securities fraud action arising from a pharmaceutical company's alleged failure to disclose reports linking its cold remedy with loss of smell

Scienter inadequately pled under the standard set forth in the PSLRA

Katten Muchin Rosenman LLP
-
USA
-
October 8 2010

The U.S. District Court for the Southern District of Indiana dismissed plaintiff’s securities fraud action against a nationwide health care benefits provider, and its officers and directors, in which plaintiff alleged that defendants artificially inflated the price of the stock by making certain false and misleading statements

DOJ announces enhanced enforcement of Foreign Corrupt Practices Act in pharmaceutical industry

Katten Muchin Rosenman LLP
-
USA
-
November 17 2009

The Department of Justice has sent a clear warning to the pharmaceutical industry: FCPA enforcement is coming

Denial of leave to amend securities complaint affirmed on basis of futility

Katten Muchin Rosenman LLP
-
USA
-
March 28 2008

The Court of Appeals for the Eighth Circuit affirmed a decision dismissing Plaintiff’s class action securities fraud complaint and denying Plaintiff leave to amend

Search results

Supreme Court rejects statistical significance as bright-line rule for materiality

Scienter inadequately pled under the standard set forth in the PSLRA

DOJ announces enhanced enforcement of Foreign Corrupt Practices Act in pharmaceutical industry

Denial of leave to amend securities complaint affirmed on basis of futility

Current Search

Suggested Facets

Author

Workarea